Glucose-stimulated insulin secretion (GSIS) involves interplay between metabolic and cationic events. Seminal contributions from multiple laboratories affirm essential roles for small Gproteins (Rac1, Cdc42, Arf6, Rab27A) in GSIS. Activation of these signalling proteins promotes cytoskeletal remodeling, transport and docking of insulin granules on the plasma membrane for exocytotic secretion of insulin. Evidence in rodent and human islets suggests key roles for lipidation (farnesylation and geranylgeranylation) of these G-proteins for their targeting to appropriate cellular compartments for optimal regulation of effectors leading to GSIS. Interestingly, however, inhibition of prenylation appears to cause mislocalization of non-prenylated, but (paradoxically) activated G-proteins, in "inappropriate" compartments leading to activation of stress kinases and onset of mitochondrial defects, loss in GSIS and apoptosis of the islet β-cell. This review highlights our current understanding of roles of G-proteins and their post-translational lipidation (prenylation) signalling networks in islet function in normal health, metabolic stress (glucolipotoxicity and ER stress) and diabetes. Critical knowledge gaps that need to be addressed for the development of therapeutics to halt defects in these signalling steps in β-cells in models of impaired insulin secretion and diabetes are also highlighted and discussed.
| INTRODUCTION
Glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells is mediated largely via the generation of soluble second messengers including cyclic nucleotides, biologically active hydrolytic products of phospholipases (A 2 , C, and D), and adenine nucleotides. [1] [2] [3] [4] However, the precise molecular and cellular mechanisms underlying GSIS remain only partially understood. Following Glut-2-mediated entry into the β-cell, glucose is metabolized via the glycolytic and tricarboxylic acid cycles with a resultant increase in intracellular ATP, which, in turn, mediates closure of ATP-sensitive K + channels localized on the plasma membrane resulting in membrane depolarization.
These signalling events promote influx of extracellular calcium through the voltage-gated calcium channels. Increase in intracellular calcium has been shown to be needed for the transport of insulinladen secretory granules to the plasma membrane for fusion and release of insulin into circulation. It is noteworthy that, in addition to adenine nucleotides, the guanine nucleotides (eg, GTP) have been shown to play major regulatory roles in GSIS. For example, using selective inhibitors of the GTP biosynthetic pathway (eg, mycophenolic acid), Metz et al 5 provided the first evidence for a permissive role for GTP in GSIS. Although the precise mechanisms underlying the regulatory role(s) of GTP in GSIS remain elusive, emerging evidence indicates that they might involve activation of one (or more)
GTP-binding proteins (G-proteins). 6, 7 At least 2 major groups of G-proteins have been described in pancreatic β-cells. The first group is trimeric in nature, which is comprised of α (39-43 kDa)-, β 
| IDENTIFICATION AND REGULATION OF SMALL G-PROTEINS AND THEIR REGULATORY FACTORS IN THE ISLET β-CELL
It is well established now that both trimeric and small G-proteins play critical roles in islet β-cell function including cytoskeletal remodeling, vesicular transport and GSIS. The reader is referred to seminal contributions from numerous laboratories, which are highlighted in. [6] [7] [8] [9] [10] [11] Briefly, based on available evidence on G-protein mediated regulation of islet function, the small G-protein family can be divided into 3 subfamilies. The first one is comprised of Rho, Rac1, Cdc42 and Arf-6.
Published evidence implicates these proteins in the cytoskeletal remodeling and vesicle fusion in the pancreatic β-cell. Rap1, Rab3A
and Rab27 belong to the second subfamily of small G-proteins. The
Rab GTPases are associated with the secretory granules and play regulatory roles in the priming and docking of insulin-laden secretory granules at the plasma membrane. Rap1 plays significant roles in β-cell functions including GSIS. Recent studies by Kelly et al 12 demonstrated that Rap1 promotes β-cell proliferation through mammalian target of rapamycin complex 1. The third group of small GTPases (eg, Rab2, Rhes and Rem2) is relatively less studied in the islet. It is noteworthy that RalA, a small G protein, appears to elicit direct regulatory effects in exocytosis via its direct interaction with the exocyst complex. Over the years, several regulatory factors/proteins have been identified in the islet β-cell that precisely regulate small G-proteins, which cycle between their inactive (GDP-bound) and active (GTP-bound) conformations. Three major types of such regulatory proteins/factors have been described for small G proteins.
The first group is comprised of guanine nucleotide exchange factors (GEFs), which facilitate the conversion of the GDP-bound (inactive)
forms to their GTP-bound (active) forms. Tiam1 and Vav2 have been identified as GEFs for Rac1 in the islet β-cell. Potential roles of these GEFs in the regulation of Rac1 function has been tested recently using novel small molecule inhibitors for Tiam1 (NSC23766) and
Vav2 (Ehop-016) ( Figure 1 ). 13 Kepner et al 14 calcium-induced calcium mobilization, insulin secretion, β-cell growth and proliferation. 16 The second group of regulatory factors are the GDP-dissociation inhibitors (GDIs), which prevent the dissociation of GDP from G proteins, and hence are considered "inhibitory" in the G protein activation cascade. Rho-GDI and caveolin-1 have been implicated to subserve the roles of GDIs for regulation of Rho, Rac1 and Cdc42 functions in the islet β-cell. 6, 7, 14 The third group represents the GTPase-activating proteins (GAPs); these proteins promote the conversion of the active G-proteins to their respective inactive conformations by activating the intrinsic GTPase function of candidate G-proteins to complete the GTP hydrolytic cycle.
| SMALL G-PROTEINS UNDERGO POST-TRANSLATIONAL MODIFICATIONS
As depicted in Figure 2 , the first of a 4-step modification includes 13 (GGTase), respectively. This is followed by proteolysis of several amino acids (up to a maximum of 3) by Ras converting enzyme 1 (Rce1), a protease of microsomal origin. A carboxylmethylation (CML) step then modifies the newly exposed carboxylate anion of the prenylated cysteine. This step is catalyzed by isoprenylcysteine carboxylmethyl-transferase (ICMT).
In some cases (not depicted in Figure 2 ), the covalent addition of a long-chain fatty acid, typically palmitate, at cysteine residues, which are upstream to the CAAX motif, completes the cascade. 7, [17] [18] [19] It is widely accepted that such modification(s) would render the modified G-proteins more hydrophobicity thereby enabling them to associate with membranes for interaction with their respective effectors.
Because the prenylation of GTPases occurs shortly after their synthesis, and due to the fact that half-lives of prenylated proteins are rather long, this is not likely to be an acute regulatory step; however, in many cases, prenylation is necessary to allow candidate G proteins to intercalate into the relevant membrane compartment. In contrast, the CML and palmitoylation steps are subject to acute regulation via addition or deletion of methyl or palmitoyl groups. The addition and removal of methyl groups are catalyzed by ICMT and esterase, respectively. Similarly, addition and deletion of palmitoyl groups are facilitated by palmitoyl transferase and esterase, respectively. 7, [17] [18] [19] Several previous studies have showed critical roles for post-translational modifications of these proteins in GSIS. 17 They are briefly discussed below.
| G-PROTEIN PRENYLATION IN ISLET β-CELL FUNCTION AND DYSFUNCTION

| Identification and functional regulation of prenyltransferases in islet β-cells
Earlier studies from our laboratory have identified at least 3 distinct prenyl transferases in the islet β-cell ( Figure 3 ). 17 The FTase and GGTase-I are referred to as CAAX prenyltransferases because their candidate substrate proteins share a conserved CAAX motif at the C-terminal region. In contrast, the GGTase-II (also termed as Rab geranylgeranyl transferase; RGGT) geranylgeranylates Rab GTPases at the CXC or CC motif, and hence referred to as the non-CAAX prenyltransferase. Structurally, FTase, GGTase-I and GGTase-II are heterodimeric consisting of α-and β-subunits. The
FTase and GGTase-I share a common α-subunit (FTase/GGTase-α), but distinct β-subunits. Experimental evidence suggests that the α-subunit is the regulatory subunit whereas the β-subunit GGTases. 7, 17 Data from these studies provided compelling evidence to implicate that protein prenylation is essential for GSIS to occur.
Observations from these pharmacological investigations implicating key functional roles of protein prenylation in GSIS were further confirmed by molecular biological approaches. They included siRNAmediated knockdown of FTase-β subunit and overexpression of an inactive mutant of FTase/GGTase-α; these experimental manipulations resulted in marked suppression of nutrient-, but not KClinduced insulin secretion from pancreatic β-cells. 
"
Published evidence from multiple laboratories implicates novel roles for Rab GTPases in physiological insulin secretion from the islet β-cell. 6, 7, 9, [23] [24] [25] In a manner akin to Ras and Rho GTPases, prenylation has been shown to regulate cellular functions of Rab GTPases in the islet. 25 The FTase catalyzes incorporation of a 15-carbon farnesyl group, while the GGTase I and GGTase II mediate incorporation of a 20-carbon geranylgeranyl group into the C-terminal cysteines of candidate G-proteins ( Figure 3 ).
In contrast to considerable evidence suggesting FTase/ GGTase I-mediated regulation of GSIS, little is known about GGTase II (also referred to as Rab GGTase; RGGT) and its regulatory proteins in the cascade of events leading to GSIS. Recent investigations from our laboratory have provided the first immunological evidence to suggest expression of α-and β-subunits of RGGT in clonal INS-1 832/13 β-cells, normal rat islets and human islets. 25 It is noteworthy that, in contrast to
Ras and Rho GTPases, the prenylation of Rab GTPases has been of key roles for RGGT and its regulatory proteins in GSIS. 25 Thus, the data from pharmacological and molecular biological approaches further validated our original hypothesis that protein prenylation represents a key signalling step in the cascade of events leading to GSIS.
| How does glucose regulate prenyltransferase activities?
The next question that we sought answers for was how physiological 
"
Based on the findings reviewed above, we propose a Working
Model, which implicates protein prenylation in physiological insulin secretion from the pancreatic β-cell. Glucose metabolism leads to increases in the levels of soluble second messenger molecules including GTP, and intermediates of isoprenoid pathway (FPP and GGPP).
Published evidence from our laboratory also suggests acute regulation (activation) of FTase/GGTase activities in a glucose-stimulated β-cell. 27 These signalling steps result in increased prenylation of key G proteins culminating in their targeting to appropriate cellular compartment (plasma membrane and secretory granule) for optimal interaction and regulation of their respective effector proteins (Raf-1, ERK1/2 and Nox2) to promote conditions (eg, ROS generation, cytoskeletal remodeling) conducive for secretory granule fusion with the plasma membrane leading to exocytotic secretion of insulin. 
| INHIBITION OF PRENYLATION RESULTS IN SUSTAINED ACTIVATION OF UNPRENYLATED G-PROTEINS IN THE ISLET β-CELL
As discussed above, the observations from the laboratories of Khan et al 35 and Dunford et al 36 have suggested that inhibition of protein prenylation leads to activation of G-proteins. Compatible with the above observations are our findings in the islet β-cell to indicate increased abundance of GTP-bound (active) Rac1 in β-cell models of glucolipotoxicity, ER stress and diabetes. 42 Furthermore, hyperactivation of Rac1 was demonstrable in human islets exposed to glucotoxic conditions and in islets derived from the ZDF rat. 43 These findings have led us to propose that Rac1 plays both positive and negative modulatory roles in the regulation of β-cell function in the sense that while it is critical for GSIS, Rac1 also exerts damaging roles under pathological conditions by inducing Nox2 activity to create excessive oxidative stress, mitochondrial damage and cell demise. 30, 42 In support of our findings implicating sustained activation of Rac1 in islet β-cell in in vitro and in vivo models of glucolipotoxicity and T2DM are recent observations by Zhou et al 44 Based on these observations, we concluded that Rac1-Nox2 signalling module plays novel regulatory roles promoting p38MAPK activation and loss of GSIS under conditions of glucotoxicity. 45 In a more recent study, Sidarala and Kowluru 46 examined roles of Rac1 in promoting activation of p53, a known apoptotic factor, in pancreatic β-cells exposed to glucotoxic conditions. Data accrued from these studies showed significant stimulatory effects of high glucose on p53 activation in INS-1 832/13 cells, normal rodent and human islets. Pharmacological inhibition of Rac1 (EHT1864 or NSC23766; Figure 1 ) significantly suppressed HG-induced p53 activation in INS-1 832/13 cells and rat islets, suggesting novel roles for Rac1 in the activation of p53. Interestingly, high glucose-induced p53 activation was also suppressed by SB203580, a known inhibitor of p38MAPK.
| SUSTAINED ACTIVATION OF RAC1 RESULTS IN STRESS KINASE ACTIVATION IN THE ISLET β-CELL UNDER CONDITIONS OF METABOLIC STRESS AND DIABETES
Together, these findings suggested that sustained activation of Rac1-p38MAPK signalling axis leads to activation of p53 leading to β-cell dysfunction under the duress of chronic hyperglycemic conditions. 46 Lastly, studies from our laboratory have confirmed above findings (ie, FTase/GGTase-α degradation, sustained activation of Rac1-Nox2 signalling module, and stress kinase activation) in islets from the ZDF rat, a model for type 2 diabetes. [41] [42] [43] We noted that levels of phosphorylated p47 
"
Based on the findings from above studies we conclude that glucotoxic/diabetic conditions promote aberrant activation of Rac1, which, in turn, leads to activation of Nox2-ROS-p38MAPK/p53/ JNK1/2 signalling pathway in the islet β-cell leading to the onset of mitochondrial dysregulation and apoptotic demise of the islet β-cell.
These findings are summarized in Figure 4 .
| DIABETES-INDUCED ALTERATIONS IN PRENYLATION OF RAB G-PROTEINS AND ASSOCIATED SIGNALLING PATHWAYS IN THE ISLET β-CELL
Recent studies by Jiang et al 47 further confirmed novel roles for prenylation of Rab G-proteins in islet function, including GSIS. Using a variety of experimental approaches they showed essential roles for geranyl geranyl pyrophosphate synthase (GGPPS), the enzyme that converts isopentenyl pyrophosphate to GGPP, in islet β-cell function during the onset of T2DM. They reported a significant increase in the catalytic activation of GGPPS in islets derived from db/db mice during the initial compensatory period followed by a significant reduction during the onset of insulin secretory abnormality. Furthermore, conditional deletion of GGPPS in the islet β-cell resulted in depletion of intracellular GGPP, geranylgeranylation and membrane targeting of Rab27A.
They also noted a marked reduction in the number of insulin-containing secretory granules beneath the plasma membrane suggesting significant defects in granule docking in GGPPS-null mice culminating in inhibition of GSIS. Over-expression of GGPPS or provision of exogenous GGPP significantly restored GSIS in islets from GGPPS-null mice, affirming the postulation that defects in GGPPS pathway (generation of GGPP, geranylgeranylation of Rab27A and granule docking) cause islet β-cell dysfunction in diabetes. 47 Indeed, these observations will form the basis for immediate investigations in the field, which might fill the knowledge gaps in our current understanding of regulatory roles of A model for Rac1-mediated, Nox2-dependent activation of p38MAPK in pancreatic β-cells under glucotoxic conditions. Based on the findings reviewed in this article, we propose a model to implicate Rac1 in Nox2-mediated activation of stress kinase (p38MAPK and p53) in pancreatic β-cells under the duress of glucotoxic conditions. Inhibition of Rac1 activation or function at the level of GEFs (EHT 1864, NSC23766 and Ehop-016) suppresses high glucose-induced activation of stress kinases. Furthermore, it appears that palmitoylation (sensitive to 2-brompalmitate; 2-BP), but not geranylgeranylation (inhibited by GGTI-2147) is necessary for high glucose-induced effects on stress kinase activation. Lastly, inhibition of Nox2 (with gp91-ds-tat peptide) markedly attenuated HG-induced Nox2 activation, ROS generation and p38MAPK activation. Together, our findings provide the first evidence to support our hypothesis that high glucose exposure conditions promote activation of Rac1, a key member of Nox2 holoenzyme, which, in turn, promotes the activation of Nox2 culminating in the generation of excessive ROS. An increase inROS leads to the onset of mitochondrial dysfunction as evidenced by caspase-3 activation, loss in metabolic function, including impaired GSIS. SB203580, a known inhibitor of p38MAPK, markedly attenuated high glucose-induced p53 activation, thus suggesting that p38MAPK activation is upstream to p53 activation. This figure is reproduced (with permission from Elsevier). 45 Note that data on Rac1-mediated activation of p53 in pancreatic β-cells under the duress of glucotoxicity, as indicated in the figure, are published recently 46 G proteins in islet biology. More importantly, these findings identify 3 important avenues for future investigations in the field. 48 First, it is likely that decreased levels of GGPP and defective catalytic function of GGPPS under diabetic conditions could result in impaired prenylation of other key signalling proteins mediated by GGTase-I (Cdc42, Rac1, Rho and Rap1) because GGPP is necessary for GGTase I-mediated prenylation of these proteins. Thus, functional inactivation of these proteins consequential to defective GGPPS could contribute to islet dysregulation. Second, geranylgeranylation of other Rab G proteins, which are substrates for GGTase-II could also be affected resulting in the dysregulation of the islet β-cell in diabetes. Third, while these investigations have focused on GGPPS, it would be interesting to critically evaluate the kinetics of FPPS activity and the intracellular concentrations of FPP in normal and diabetic islet β-cells to determine contributory roles of these signalling proteins in islet function in health and diabetes. It should be also kept in mind that decreased GGPPS activity, as shown in the diabetic islet β-cell, could result in increased levels (accumulation) of FPP, which, in turn could lead to farnesylation of proteins. 48 It is notable that the studies of Jiang et al 47 In addition, each of these subunits is regulated by post-translational modification steps for optimal function. For example, the α-subunits undergo ADP-ribosylation, myristoylation, palmitoylation. 7 Gβ subunits have been shown to be regulated via histidine phosphorylation 50 and Gγ subunits are modified by farnesylation/geranylgeranylation. 7, 18 These modification steps not only control the association and stability of the αβγ trimer but also their catalytic function.
| ROLES OF TRIMERIC G-PROTEINS AND REGULATORS OF G-PROTEIN SIGNALLING (RGS) IN ISLET FUNCTION IN HEALTH AND DIABETES
Besides these signalling events, several regulatory factors/proteins for the GPCR-G-protein coupling, activation (by GEFs) and termination and function (by RGS) have been identified in the islet β-cells.
Original contributions from the author's laboratory provided evidence for acute regulation of histidine phosphorylation of Gβ subunits and farnesylation/geranylgeranylation of Gγ subunits under conditions favourable for GSIS. 50 Follow-up studies have also showed significant reduction in histidine kinase activities in islets derived from animal models of type-2 diabetes (ZDF rat and GK rat). 50 Specific examples of trimeric G-proteins and RGSs in islet β-cells in health and in models of impaired insulin secretion are provided in Table 1 . Clearly, additional studies are needed to provide clarity of contributory roles of these proteins in islet function.
| CONCLUSIONS AND FUTURE DIRECTIONS
Based on the published evidence from multiple laboratories it can be concluded that small G-proteins play significant roles in normal islet Based on these observations it was concluded that Rac1/Nox2-dependent CD36 expression contributes to β-cell dysfunction and Fluoride, a known activator of trimeric G-proteins, induced apoptosis in RINm5F cells and normal rat islets. Potential involvement of G-proteins was confirmed by culture of β-cells with Ptx prior to exposure to fluoride.
52
The β-subunit of trimeric G-proteins underwent phosphorylaton at a histidine residue in the membrane and secretory granule fraction in pancreatic β-cells. Incubation of phosphorylated β-subunit with Gα. GDP accelerated the dephosphorylation of the β-subunit, accompanied by the formation of Gα .GTP . This is the first evidence for a non-receptor-mediated activation of trimeric G-proteins by glucose in the pancreatic islet. 53 Overexpression of G11α and PLCβ1 or PLCβ3 did not affect glucose-or carbachol-stimulated insulin secretion in INS-1 and βG40/110 cells. These findings suggested no correlation between inositol triphosphate accumulation and insulin secretion. 54 Insulin secretion elicited by glucose, KCl and mitochondrial fuels was significantly blunted in islets from the GK rat. Mastoparan, a global activator of trimeric G-proteins circumvented such a secretory defect. These findings suggested a defect late in stimulus-secretion coupling is responsible for insulin secretory defects in this animal model. 55 Glucotoxic conditions reduced the ADP ribosylation of Gα s and Gα olf subunits in the membrane fraction in HIT-T15 cells and (fed or fasted) rodent islets. It was concluded that defects in cAMP-dependent insulin secretion under the duress of glucotoxicity may, in part, be due to reduced ADP ribosylation of specific Gα subunits. 56 Expression levels of Gα s and Gα olf , adenylyl cyclases 1 and 3 are significantly higher in GK rat islets compared with their control counterparts.
57
Gα z -null mice exhibited increased glucose clearance following intraperitoneal and oral glucose challenge as compared with WT controls. Islets isolated from these mice also exhibited increased GSIS compared with those of WT mice. It was concluded that Gα z is negative regulator of insulin secretion. 58 siRNA-regulator of G-protein Signalling4 (RGS4) expression in MIN6 cells resulted in significantly higher M3 muscarinic receptor-mediated GSIS and calcium release. These findings were replicated in islets derived from RGS4-deficient mice. Based on these and additional supporting evidence, it was concluded that RGS4 plays a negative modulatory role in in vitro and in vivo models of insulin secretion. 59 Whole pancreas or β-cell-specific Gα s deficiency leads to early-onset insulin-deficient diabetes with a severe defect in β-cell proliferation. These findings provide compelling evidence in support of critical roles of Gα s signalling in β-cell growth and function. 60 Gα o2 deficient mice, but not Gα o1 or Gα i deficient mice exhibited higher glucose clearance more efficiently than WT mice via increased GSIS.
61
Gα z -deficient mice are resistant to developing glucose intolerance following a high fat diet. These mice also exhibited increased β-cell proliferation and β-cell mass. 62 Regulator of G-protein Signalling16 (RGS16) is abundantly expressed in pancreatic β-cells. Overexpression of RGS16 augmented GSIS in mouse and human islets suggesting a critical regulatory role for this protein in physiological insulin secretion. siRNA-RGS16 inhibited GSIS. Based on additional experimental evidence it was concluded that RGS16 plays a positive modulatory role of β-cell function including insulin secretion and proliferation by suppressing inhibitory signals elicited by somatostatin derived from the δ-cell of the islet.
63
Abbreviation: GSIS, glucose-stimulated insulin secretion; WT, wild-type.
FIGURE 5
Proposed model for ROS-dependent activation of MAPKinases. We propose that a tonic increase in Nox2-mediated ROS generation favours cytoskeletal remodeling, insulin secretion and cell proliferation events. Low-levels of ROS activate proliferative ERK signalling under the regulatory control of Ras. In contrast, sustained activation of Nox2 results in increased levels of ROS, which, in turn, promote Rac1-induced activation of apoptotic JNK1/ 2, and inhibit ERK1/2 signalling pathways. Additional studies are needed to further validate this model (Reproduced with permission from Bentham-Science) 64 demise under the duress of hyperglycemia. 74 Interestingly, recent studies by Gharib et al reported significant reduction in obesityinduced oxidative stress in the heart in a CD36 deficient animal model. between plasma membrane and endomembranes and proteinprotein interactions. Therefore, it is conceivable that defects in Rac1 is significantly activated in diabetic hearts following ischemia-reperfusion injury compared with the non-diabetic hearts. Perfusion with NSC23766 prevented diabetes-induced effects. Inhibition of Rac1 also prevented activation of Nox2 and associated ROS production and protein carbonyl accumulation. 67 Incubation of INS-1 832/13 cells with a mixture of pro-inflammatory cytokines Interleukin-1β + Interferonγ + Tumor necrosis factorα (IL-1β + IFNγ + TNFα) resulted in a significant activation of Rac1 and Nox2 leading to a loss in mitochondrial membrane potential. siRNA-p47 phox or apocynin, a known inhibitor of Nox2, markedly suppressed cytokine-induced effects. Coprovision of NSC23766 alleviated cytokine-induced Rac1 activation and mitochondrial defects. Rac1-Nox2 signalling pathway is accelerated in retina derived from Stz-diabetic rats and mice leading to increased ROS generation and mitochondrial damage. Similar increases in Rac1 activation and p47 phox expression are noted in retinal microvasculature from human donors with established diabetic retinopathy. Treatment of diabetic mice with NSC23766 prevented retinal Rac1 activation and ROS generation.
69
NSC23766 prevented post-ischemic neuronal apoptosis in Stz-induced diabetic rats. NSC23766 also prevented cerebral ischemia-induced mitochondrial p53 translocation and expression of p53-upregulated modulator of apoptosis. 70 Exendin-4 significantly alleviated angiotensin II-induced H 2 O 2 generation, expression of p53, p21 and associated senescence in VSMC. NSC23766 abrogated the suppressive effects of Exendin-4 on angiotensin-II-induced H 2 O 2 generation and premature senescence of VSMC.
71
Glucotoxic conditions promoted activation of Rac-Nox2 signalling pathway leading to activation of downstream signalling events including activation of p38MAPK in normal rat islets and INS-1 832/13 cells. NSC23766 markedly suppressed high glucose-induced p38MAPK activation. 45 Glucotoxic conditions promoted activation of p38MAPK in retinal endothelial cells. Consistent with these observations, a significant increase in p38MAPK was seen in retina from Stz-induced mice. NSC23766 inhibited high glucose-induced p38MAPK in cultured retinal endothelial cells. 72 Administration of NSC23766 significantly prevented the development of spontaneous diabetes in the non-obese diabetic (NOD) mouse model. Furthermore, NSC23766 suppressed expression of Rac1 and CHOP (a marker for endoplasmic reticulum stress) in islets from the diabetic NOD mice. 73 Glucotoxic conditions induced activation of Rac1-Nox2 signalling axis resulting in increased expression of CD36 (a fatty acid transporter) culminating in apoptosis in INS-1 cells and human β-cells (1.1B4). NSC23766 significantly attenuated high glucose-induced Rac1-Nox2 activation, CD36 expression and mitochondrial dysfunction in these cells.
74
NSC23766 markedly suppressed high glucose-induced p53 activation in normal rat islets and INS-1 832/13 cells.
46
Abbreviations: ROS, reactive oxygen species.
